Company Overview and News

31
Ametek: Excellent Fundamentals, High Valuation

13h seekingalpha
AMETEK is a global manufacturer of electronic instruments and electromechanical devices with around $4.5 billion in annual revenues.
ROP STQN AME

164
Top Stock Reports for Mastercard, NVIDIA & Danaher

2018-05-14 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), NVIDIA (NVDA) and Danaher (DHR). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
STQN ADP MA NVDA BRK.A ADPVV GM.WS.A GM.WS.B GM.WS.C ICE GM OXY GM.WSB DHR MODN

0
Another Record Year for Frutarom - Continues to Successfully Implement its Rapid & Profitable Growth Strategy Record Sales, Profit, Cash Flow and Earnings per Share

2018-03-20 globenewswire
Frutarom Expects 2018 to be Yet Another Record Year, as it Continues to Improve its Profitability, also through Projects for Combining Plants and Resource Optimization, and the Successful Completion of the Enzymotec Acquisition
FRUT STQN

65
4 Reasons to Include Legg Mason (LM) in Your Portfolio Now

2018-03-14 zacks
With prudent cost management and strong inorganic growth strategies, Legg Mason (LM - Free Report) appears a solid bet now. Further, the company's focus on expanding product offerings for its customers bode well for the long term.
STQN MS.PRE MS.PRF MS.PRG LMHA MS.PRA VRTS LMHB AMP MS.PRI MS.PRK WDR MS LM

19
Entegris, Inc 2017 Review

2018-03-13 seekingalpha
Entegris, Inc. (ENTG) is a global developer, manufacturer and supplier of microcontamination control products, specialty chemicals and advanced materials handling solutions for manufacturing processes in the semiconductor and other high-technology industries. The company's mission is to leverage their unique breadth of capabilities to create value for their customers by developing mission-critical solutions to maximize manufacturing yields, reduce manufacturing costs and enable higher device performance.
SSNLF ENTG STQN BC94 SMSN SMSD

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...